The content on this site is intended for healthcare professionals only
Prof Kenneth Anderson speaks to ecancer.tv about the substantial advances that have been made in the availability of haemato-oncological treatments.
Prof Anderson also outlines promising new research looking at the inhibition of proteasomes and aggresomes and discusses the importance of the patient microenvironment, the role this plays in cancer progression and the way that this can be targeted to improve treatment.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Treating relapsed multiple myeloma outside of use of T-cell redirected therapies
Guiding transplant decisions in multiple myeloma with MRD
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
